AbbVie Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? AbbVie Inc trades at $247.41 (market cap $441.94B), while ZIM Integrated Shipping Services Ltd trades at $25.26 (market cap $2.96B). The key difference: AbbVie Inc is far larger — about 149.3× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays the higher dividend (20.16%). Which is the better fit depends on your goals.
| ABBV | ZIM | |
|---|---|---|
Market Cap | $441.94B | $2.96B |
Sector | Health | Industrials |
52-Week High | $263.58 | $29.27 |
52-Week Low | $197.38 | $12.44 |
Enterprise Value | $506.19B | $6.81B |
Dividend Yield | 2.77% | 20.16% |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
ZIM Integrated Shipping Services trades at $24.91, down 1.19% for the day, with a bearish technical outlook and mixed fundamental picture. The stock shows attractive valuation metrics including P/S of 0.47 and P/B of 0.77, but faces profitability challenges with a 1.56% net margin. Recent Q1 2026 earnings missed expectations, while Q2 results are anticipated amid merger uncertainty with Hapag-Lloyd.
The outlook remains cautious with analyst consensus evenly split between Hold and Sell ratings and a $16.75 price target well below current levels. Key risks include regulatory hurdles for the proposed merger, declining revenue projections, and volatile shipping rates. The company's strong cash position provides some downside protection, but near-term headwinds outweigh growth catalysts.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →